Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.

International journal of cancer - 15 Mar 2019

Saeed Khalid, Ojamies Poojitha, Pellinen Teijo, Eldfors Samuli, Turkki Riku, Lundin Johan, Järvinen Petrus, Nisen Harry, Taari Kimmo, Af Hällström Taija M, Rannikko Antti, Mirtti Tuomas, Kallioniemi Olli, Östling Päivi

Abstract excerpt

Renal cell cancer (RCC) has become a prototype example of the extensive intratumor heterogeneity and clonal evolution of human cancers. However, there is little direct evidence on how the genetic heterogeneity impacts on drug response profiles of the cancer cells. Our goal was to determine how genomic clonal evolution impacts drug responses. Finding from our study could help to define the challenge that clonal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3T3 Cells
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clonal Evolution

Share to Coculture Techniques

Share to DNA Copy Number Variations

Share to Drug Screening Assays, Antitumor

Share to Kidney Neoplasms

Share to Primary Cell Culture

Source

Identifiers

PMID: 30125350
DOI: 10.1002/ijc.31815

Genes

PDC
PBRM1
TSC2
VHL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.PMID 30125350Read ↗

Multilayered molecular profiling supported the monoclonal origin of metastatic renal cell carcinomaSemantic proximity Read ↗

Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinomaSemantic proximity Read ↗

Clonal morphology-guided combination therapies overcome heterogeneity-driven drug toleranceSemantic proximity Read ↗

Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor TherapySemantic proximity Read ↗

Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

A unifying framework disentangles genetic, epigenetic, and stochastic sources of drug-response variability in an <i>in vitro</i> model of tumor heterogeneitySemantic proximity Read ↗

Distinct Molecular Profiles and Drug Vulnerabilities in Pancreatic Metastases of Renal Cell CarcinomaSemantic proximity Read ↗

Tumor Heterogeneity, Single-Cell Sequencing, and Drug ResistanceSemantic proximity Read ↗

Tumor heterogeneity and personalized cancer medicine: are we being outnumbered?Semantic proximity Read ↗

Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis.Semantic proximity Read ↗

Adapting clinical paradigms to the challenges of cancer clonal evolution.Semantic proximity Read ↗

Tumour heterogeneity and the evolution of polyclonal drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.